The Prodrug Platin‐A: Simultaneous Release of Cisplatin and Aspirin |
| |
| Authors: | Dr Rakesh K Pathak Sean Marrache Joshua H Choi Trenton B Berding Prof?Dr Shanta Dhar |
| |
| Affiliation: | 1. NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602 (USA) http://shanta.chem.uga.edu;2. Department of Physiology and Pharmacology, University of Georgia, Athens, GA 30602 (USA) |
| |
| Abstract: | Cancer‐associated inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo‐anti‐inflammatory strategy is of interest for the management of aggressive cancers. The platinum(IV) prodrug Platin‐A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin. Platin‐A exhibited anticancer and anti‐inflammatory properties which are better than a combination of cisplatin and aspirin. These findings highlight the advantages of combining anti‐inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug. |
| |
| Keywords: | antitumor agents drug design inflammation platinum prodrugs |
|
|
